Sungkyunkwan University · Medicine
Professor Soo-Youn Lee's research lab specializes in pharmacogenomics, personalized medicine, and molecular mechanisms underlying disease progression, with a focus on identifying genetic and metabolic biomarkers for precision therapy. The lab investigates genetic polymorphisms—particularly in drug-metabolizing enzymes like CYP2D6—and their clinical implications in diverse populations, including Koreans. It also explores molecular pathways involved in fibrosis, neurodegeneration, and cancer tropism, integrating genomics, proteomics, and metabolomics to uncover novel therapeutic targets. The lab's work bridges basic science and clinical application, aiming to improve diagnostic accuracy and treatment outcomes in conditions such as congenital adrenal hyperplasia, major depressive disorder, and brain tumors.
Figures are computed from collected data and may differ slightly.
For clinical application of pharmacogenetic tests, quantitative prediction of enzyme activity based on accurate determination of genotype is essential. There has been limited information available on the genetic polymorphism of CYP2D6 in the Korean population. In this study, CYP2D6 genotypes were assessed in 400 Korean subjects. Twenty-eight different CYP2D6 alleles and 35 genotypes were detected. On the basis of the genotype determined, the frequency of poor metabolizers and ultrarapid metaboli
The current results indicated that a genome-wide pharmacogenomic approach is useful for identifying novel polymorphism predictors of severe OXCPN that may be used in personalized chemotherapy.
We conclude that COMP-Ang1 delayed the fibrotic changes in the kidney of diabetic db/db mice through its anti-inflammatory or metabolic effects.
Metabolism of amino acids, including ABA and glutamic acid, has the potential to contribute to understandings of pathogenesis and predictions of therapeutic response in MDD.
We recently reported that hNSCs (human neural stem cells) have the interesting characteristic of migration towards an intracranial glioma. However, the molecules and mechanisms responsible for tumour tropism are unclear. In the present study, we used microarray and proteomics analyses to identify a novel chemoattractant molecule, TIMP-1 (tissue inhibitor of metalloproteinase-1), secreted from human brain tumour tissues. We demonstrate that TIMP-1 significantly enhances hNSC adhesion and migratio
Our data showed that steroid profiling reduced the burden of follow-up exams by improving the positive predictive value of the CAH screening program. The use of steroid profiling as a second-tier test for positive CAH screening will improve clinical practice particularly in a tertiary care hospital setting where positive CAH screening from preterm neonates is frequently encountered.
Open papers in the app to read, cite, and organize with AI.
